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Summary
In order to enhance vaccine uptake by the immune cells in vivo, molecular engineering approach
was employed to construct a polymeric immunoglobulin G scaffold (PIGS) that incorporates
multiple copies of an antigen and targets the Fc gamma receptors on antigen-presenting cells.
These self-adjuvanting immunogens were tested in the context of dengue infection, for which
there is currently no globally licensed vaccine yet. Thus, the consensus domain III sequence
(cEDIII) of dengue glycoprotein E was incorporated into PIGS and expressed in both tobacco
plants and Chinese Ovary Hamster cells. Purified mouse and human cEDIII-PIGS were
fractionated by HPLC into low and high molecular weight forms, corresponding to monomers,
dimers and polymers. cEDIII-PIGS were shown to retain important Fc receptor functions
associated with immunoglobulins, including binding to C1q component of the complement and
the low affinity Fcc receptor II, as well as to macrophage cells in vitro. These molecules were
shown to be immunogenic in mice, with or without an adjuvant, inducing a high level IgG
antibody response which showed a neutralizing potential against the dengue virus serotype 2.
The cEDIII-PIGS also induced a significant cellular immune response, IFN-c production and
polyfunctional T cells in both the CD4+ and CD8+ compartments. This proof-of-principle study
shows that the potent antibody Fc-mediated cellular functions can be harnessed to improve
vaccine design, underscoring the potential of this technology to induce and modulate a broad-
ranging immune response.
Introduction
As the development of safe and potent adjuvants has been a
major bottleneck in vaccine development against many dis-
eases, our focus in recent years has been to generate
adjuvanticity by molecular engineering, and in that way
minimize the vaccine’s reliance on powerful exogenous adju-
vants that may have undesirable toxic effects. Such self-
adjuvanting vaccines might be sufficiently immunogenic on
their own or could be applied with currently available, licensed
adjuvants such as alum. Here, we employed an approach based
on a polymeric IgG-Fc fusion protein (Mekhaiel et al., 2011;
Smith and Morrison, 1994) to design an immune complex-like
molecule modelled on pentameric/hexameric IgM, for efficient
delivery of multiple copies of consensus domain III (Leng et al.,
2009) of the dengue envelope glycoprotein to Fc-gamma
bearing antigen-presenting cells (APC). Dengue epidemic
requires urgently a cheap and globally applicable vaccine, as
there are around 400 million people around the world currently
infected, while almost half of the human population is at risk
(Lam, 2013). Despite substantial efforts to develop a dengue
vaccine in recent years (Beckett et al., 2011; Coller and
Clements, 2011; Danko et al., 2011; Guy et al., 2011; Lindow
et al., 2013; Murphy and Whitehead, 2011; Osorio et al.,
2011), progress has been frustratingly slow. An important
complication has been the need to induce protective immunity
against all four known serotypes of the dengue virus, while
circumventing the issue of serotype cross-immunity, which can
lead to antibody-dependent enhancement (ADE) of infection
(Balsitis et al., 2010; Chau et al., 2008; Kliks et al., 1988; Moi
et al., 2013). The latter phenomenon occurs during both
natural infection and suboptimal vaccine-induced immune
responses and can lead to more severe manifestations of the
subsequent infection. The Dengvaxia vaccine developed by
Sanofi Pasteur (Schwartz et al., 2015) and based on attenuated
yellow fever virus performed sufficiently well in two large
efficacy trials in South-East Asia and Latin America (Capeding
et al., 2014; Villar et al., 2015), and in the three-year follow-up
studies (Hadinegoro et al., 2015) to warrant its recent licensure
in Mexico, Brazil and Philippines. However, the vaccine was less
effective in children younger than 9 years. Furthermore, the
follow-up studies suggested that the incidence and severity of
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dengue infection were worse in children from the vaccinated
than the control group, most likely due to ADE. Coupled with
the relatively poor protection against the DENV2 serotype, this
clearly illustrates the difficulties and challenges for developing a
universal dengue vaccine. In fact, it may well be that an
effective dengue vaccination strategy may require multiple
vaccines aimed at different age groups or populations.
To minimize the risk of ADE, the target of many new vaccine
approaches has been the domain III of the viral envelope
glycoprotein E, which induces relatively lower levels of non-
neutralizing antibodies than the other domains (Guzman et al.,
2010). Mouse sera induced by a DIII-based DNA vaccine were
also highly reactive to infective viral particles in a virus-capture
ELISA and specific for each serotype as revealed by the low
cross-reactive and cross-neutralizing activities (Poggianella
et al., 2015). The serotype-specific sera did not induce antibody
dependent enhancement of infection (ADE) in non-homologous
virus serotypes. Furthermore, it has been previously shown that
the consensus domain III (cEDIII) can induce antibodies to all
four serotypes and therefore simplify vaccine design consider-
ably (Leng et al., 2009), dispensing with the need for a
tetravalent vaccine, with its attendant issues of complexity of
production and serotype interference. cEDIII was originally
generated by aligning the EDIII sequences from each of the
four serotypes in five clinical isolates for each serotype (Leng
et al., 2009). Unfortunately, domain III is notoriously poorly
immunogenic and requires powerful adjuvants to induce
neutralizing antibodies (Chen et al., 2013; Chiang et al.,
2011, 2014; Harahap-Carrillo et al., 2015; Hermida et al.,
2006). Here, we set out to test whether the PIGS bioengi-
neering approach could improve the immunogenicity of cEDIII
and induce a broad immune response to this antigen, which
could then be harnessed in vaccine design for dengue
infection. We chose to use both the plant and mammalian
expression system, for comparison purposes, with the former
also intended for potential scale-up production of such
molecules at comparatively lower costs.
Results
Genetic construction for cEDIII-PIGS
The genes encoding the cEDIII-PIGS single chain protein were
cloned and expressed both in genetically modified N. ben-
thamiana and mammalian CHO cells. Both mouse (based on
IgG2a) and human (based on IgG1) version of these molecules
were generated. The linear depiction of the cloned cEDIII-PIGS
sequence is shown in Figure 1a. cEDIII antigen replaced the
variable region of the immunoglobulin c chain molecule. The
antigen is linked to Cc2 and Cc3 domains by a short peptide
derived partly from Cc1 domain and partly from the hinge
region. The ltp is genetically linked at the C’ terminus. Two
amino acid substitutes were added: a serine at position 230
(human) to avoid an unpaired cysteine residue and a threonine
at position 476 (murine and human) to mimic the C terminus
of IgM CH4 domain. cEDIII-PIGS are expected to form IgG-like
structures as shown in Figure 1b, with the dengue cEDIII
antigen on the N terminal end and the IgM-derived l tail piece
on the C terminal end. The latter can facilitate polymerization
of the monomers to form dimers and higher polymers (i.e.
hexamers), much like the IgM itself. Furthermore, if co-
expressed with the J chain, these molecules can form IgM-
like pentamers.
Expression of cEDIII-PIGS in plants and CHO cells
Mouse cEDIII-PIGS molecules were expressed in N. benthamiana
plants by infiltration of plant leaves with corresponding pTRAk.2
vector. After 6 days, the plant leaves were harvested, protein
extract was prepared and analysed by SDS-PAGE and Western
blotting with detection by anti-IgG heavy chain antiserum (Fig-
ure 2a upper panel) or anti-dengue monoclonal antibody (Fig-
ure 2a, lower panel) under non-reducing (NR) or reducing (R)
conditions. Under non-reducing conditions, the murine cEDIII-PIGS
presented as immunoreactive protein bands of varying sizes
ranging from 40 to 80 kDa and several molecular forms of
160 kDa and above (Figure 2a, NR). In the presence of J chain
(lane +J), there was a higher proportion of polymeric forms, when
compared to constructs without J chain (lane J). Consequently,
the J chain version of the cEDIII-PIGS derived from plant was used in
the subsequent studies. Under reducing conditions, a predominant
40 kDa single chain polypeptide was observed (labelled ‘S’), with
evidence of some degradation (i.e. the 28 kDa protein band).Wild-
type plant extracts (lane ‘wt’) and commercial mouse IgG2a (lane
‘pc’, upper panel) were used as the internal negative and positive
controls, respectively. When probed with an anti-dengue antibody
(Figure 2a, lower panel), the specific protein profiles were very
similar to those seen with anti-IgG antibody (Figure 2a, upper
panel), thus confirming the presence of the antigen within the
cEDIII-PIGS molecules. Wild-type plant extract (lane ‘wt’) showed
no immunoreactivity with the anti-dengue antibody, while the
bacterially expressed dengue cEDIII antigen (lane ‘pc’, lower panel)
served as the positive control. The cEDIII-PIGS were also expressed
in CHO cells, and several cell clones were generated. A dominant
protein band corresponding tomonomer (80 kDa)was detected by
both IgG antiserum and dengue antibody in the supernatant of
transfected cells, while only a weak protein band was detected for
the dimer (Figure 2b). We also expressed the human version of
cEDIII-PIGS in plants. Similar tomouse cEDIII-PIGS, the presence of J
chain increased the proportion of the polymeric forms detected
with anti-IgG heavy chain antiserum (Figure 2c, upper panel) or
anti-dengue antibody (lower panel). However, human cEDIII-PIGS
showed a significantly higher proportion of polymeric forms than
the mouse cEDIII-PIGS (lanes +J, two infiltrated plants). Human
IgG1 served as thepositive controlwhilewild-type plant extractwas
used as the negative control.
Purification and HPLC analysis of cEDIII-PIGS
Murine cEDIII-PIGS molecules were purified from plant extracts or
CHO cell culture supernatants using affinity chromatography. The
final yields were 17 mg/kg fresh weight plant tissue, or 2.5 mg/L
CHO culture supernatant, respectively. After concentration,
typically to 1 mg/mL, plant-derived murine and human cEDIII-
PIGS were subjected to HPLC fractionation of low and high
molecular weight forms (Figure 3). Fractionated components
were analysed by comparison with gel-filtration protein standards
(Figure 3a) and by SDS-PAGE/Coomassie staining and Western
blotting (Figure 3b). HPLC profiles indicated that high molecular
weight fraction of mouse cEDIII-PIGS contained a mixture of
molecular species ranging from dimers (expected size 160 kDa) to
polymers (expected size 480 kDa), although SDS-PAGE and
Western analysis (Figure 3b) revealed predominantly a diffuse
150–250 protein band likely corresponding to dimers and trimers,
in addition to some truncated forms. The low molecular weight
fraction contained a mixture of monomer (80 kDa) and various
truncated forms (50–70 kDa), which could not be separated.
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Human cEDIII-PIGS displayed exclusively polymers in the high
molecular weight fraction, ranging from the expected 480–
680 kDa, possibly representing pentamers/hexamers and some
higher molecular conjugates, respectively. This fraction also
contained large molecular aggregates (>1000 kDa). Low molec-
ular weight fraction contained monomers and a truncated forms.
SDS-PAGE and Western blot analysis (Figure 3b) of the high
molecular weight fraction of human cEDIII-PIGS indicated the
presence of a diffuse protein band of 250 kDa and above but the
exact size could not be determined.
Functional characterization of cEDIII-PIGS
To characterize these molecules functionally, the cEDIII-PIGS were
tested in three binding assays. In the first, their potential to bind
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Figure 1 Construction of cEDIII-PIGS. (a) Linearized map of murine c2a and human c1based cEDIII-PIGS sequence showing the key genetic elements; (b)
schematic illustration of the basic cEDIII-PIGS constituent (the ‘monomer’), and the higher molecular structures represented by the dimer and polymers
(hexamers). The position of the dengue antigen in place of antibody variable region and the binding domains for C1q and Fc receptor are indicated in the
monomer construct. The expected molecular weights of each construct are indicated.
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Figure 2 Expression of murine and human cEDIII-PIGS. Western blot detection of murine (a), in plants; (b), in CHO cells) and human (c), in plants) cEDIII-
PIGS by anti-Ig c antiserum (upper panels) or by anti-dengue (lower panels) monoclonal antibodies. Lanes: ‘pc’, (positive control) mouse IgG2a (a, b) or
human IgG1 (c) (upper panels) or bacterially expressed recombinant cEDIII (lower panels); ‘wt’: wild-type plant extract; J: cEDIII-PIGS expressed without J
chain; +J: cEDIII-PIGS expressed with J chain. The proteins were electrophoretically resolved under the non-reducing (NR) or reducing (R) conditions.
Indicated are the different molecular forms present in the cEDIII-PIGS preparations: P—polymer; D—dimer; M—monomer; S—single chain; T—truncated
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the C1q component of complement cascade was tested by ELISA
(Figure 4a). Both the plant and CHO-derived unfractionated
cEDIII-PIGS bound to C1q in a concentration-dependent manner.
PBS and murine IgG2a used as the negative control did not bind,
while ICM (immune complex mimics), which contains multiple
copies of a murine IgG1 mAb bound to a polymeric Mycobac-
terium tuberculosis antigen (Pepponi et al., 2013), was used as
the positive control. In the second assay, we tested the capacity of
fractionated mouse polymeric and monomeric cEDIII-PIGS to bind
to the immobilized mouse FccRII (CD16), in a Biacore assay.
Polymeric cEDIII-PIGS bound with a fast ‘on’ and slow ‘off’ rate,
whereas the monomeric form bound less effectively to the same
receptor (Figure 4b). Finally, in the third assay, we tested the
capacity of cEDIII-PIGS polymers to bind to Fcc receptor positive
(J774 macrophages) and negative (NIH-3T3 fibroblasts) cells.
Figure 4c shows the binding of cEDIII-PIGS to J774 (blue
histogram) but not to NIH-3T3 cells, when compared to
secondary antibody alone (red histogram). This binding could be
reversed to a large degree by cell preincubation with the blocking
anti-CD16/32 antibodies, thus confirming the specificity of FccR
binding.
ELISA analysis of IgG response to cEDIII-PIGS in mice
Dengue-specific IgG responses in mice were determined by ELISA
after each immunization. cEDIII alone was not immunogenic, but
with alum, a strong IgG response was observed. The cEDIII-PIGS
were immunogenic with and without alum, although peak
responses were accelerated by the addition of alum (Figure 5a).
The relative proportions of IgG1 and IgG2a were also determined
(Figure 5b) and showing that IgG1 was produced at significantly
higher levels than IgG2a. After third and final immunization, the
end-point titres for cEDIII-PIGS were determined by serial
dilutions. These were found to be 3.9 9 105 (plant) and
7.8 9 104 (CHO), respectively, while in the presence of alum,
these were 1.5 9 106 (for both plant and CHO-derived cEDIII-
PIGS) (Figure 5c). Finally, we tested whether the IgG responses
was directed exclusively to the cEDIII antigen or whether some
reactivity may have been directed to the PIGS platform due to
altered glycosylation in plants or the presence of neo-epitopes.
Immune sera detected both cEDIII and cEDIII-PIGS in dilution-
dependent manner (Figure 5d). In contrast, when presaturated
with recombinant cEDIII, the same sera could no longer detect
either, thus confirming that all of the antibody reactivity was
directed towards the cEDIII antigen alone.
Dengue neutralization assay
To test the neutralizing potential of cEDIII-PIGS-induced antibod-
ies, a neutralization assay using dengue virus serotype 2 was
performed (Figure 6). While only one of the animals from the
groups immunized with cEDIII alone or CHO-derived cEDIII-PIGS
developed DENV2 neutralizing antibodies, neutralization was
observed in 3/9 animals immunized with plant-derived cEDIII-
PIGS. Inclusion of alum in the immunization regimen resulted in
the sero-neutralizing conversion of three animals from the cEDIII
group but 5/8 and 8/9 animals from the plant- and CHO-derived
cEDIII-PIGS groups, respectively.
T-cell proliferation and cytokine responses
T-cell proliferation was determined in antigen-stimulated spleno-
cyte cultures by 3[H]-thymidine incorporation. As can be seen in
Figure 7a, there was no significant T-cell proliferation in antigen-
alone immunized mice group, but the stimulation index was
significantly higher for cEDIII-PIGS immunized mice (eight for
plant and 15 for CHO-derived PIGS). In the presence of alum, all
groups induced high level T-cell proliferation, as indicated by
indices above 10. Concanavalin A served as the positive control
for cell proliferation. The analysis of IFN-c production in the
supernatants from these splenocyte cultures indicated that
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truncated (T) form.
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cEDIII-PIGS induced high levels of this Th1 cytokine with or
without alum, although plant-derived cEDIII-PIGS were superior
to CHO-derived cEDIII-PIGS (Figure 7b).
cEDIII-PIGS induce multifunctional T cells
As cEDIII-PIGS induced robust IFN-c responses in whole spleno-
cytes, we next interrogated type 1 cytokine production more
comprehensively at the cell-specific level. Polyfunctional T cells are
defined as cells capable of producing multiple effector cytokines
and are a widely acknowledged biomarker of protection against
several evolutionarily disparate pathogens (Seder et al., 2008).
Hence, we assessed whether cEDIII-PIGS could induce these cells
after immunization. Splenocytes from each mouse immunization
group were pulsed with cEDIII recall antigen, and flow cytometric
analysis was used to measure intracellular cytokine responses
(IFN- c, IL-2 and TNF-a, i.e. cytokine ‘functions’) in CD4+ and
CD8+ T cells, using the gating strategy as shown in (Figure 8a).
In CD4+ T-helper cells, it was found that cEDIII immunization in
the absence of adjuvant elicited a predominantly monofunctional
response (0.038%) and a modest proportion of double-positive
cells (0.013%) (Figure 8c). Interestingly, plant-derived cEDIII-PIGS
induced a lower percentage of monofunctional cells (0.027%) yet
a higher percentage of double-positive cells (0.027%) compared
to native cEDIII. CHO-derived cEDIII-PIGS were found to induce a
balanced profile of single- (0.017%), double- (0.010%) and
triple-positive (0.012%) cells. The addition of alum ablated the
monofunctional cells in cEDIII-immunized mice, yet produced the
emergence of a triple-positive population (0.010%) in the plant-
derived cEDIII-PIGS group. In the CHO-derived cEDIII-PIGS group,
the use of adjuvant caused a sharp increase in the percentage of
double-positive cells (0.056%).
In the CD8+ cytotoxic T-cell compartment, responses were
overall more muted compared to CD4+ T cells (Figure 8b).
Immunization with cEDIII alone induced only double-positive cells
either with (0.027%) or without (0.025%) adjuvant, whereas the
inclusion of adjuvant boosted monofunctional cytokine responses
in the plant-derived cEDIII-PIGS group (0.036%–0.052%). For
CHO-derived cEDIII-PIGS immunization, the adjuvant group had a
high proportion of triple-positive cells (0.012%) that was absent
in other groups. Summation of total T-cell polyfunctionality can
be seen in (Figure 8b), showing that cEDIII-PIGS immunization
induced T cells with superior CD4+ T-cell functionality (i.e. triple
positive) compared to antigen alone.
Discussion
Live, attenuated virus-based dengue vaccines have been shown to
be very immunogenic but their use in certain populations such as
young children, the key group targeted for vaccination and
immunocompromized individuals, remains uncertain. Coupled
with suboptimal performance in recently completed human
clinical trials, there is a need to develop alternative strategies,
including potentially subunit vaccines. In the last year alone,
several such vaccine candidates have been reported (Govindara-
jan et al., 2015; Manoff et al., 2015; Mareze et al., 2015;
Poggianella et al., 2015; Suphatrakul et al., 2015) and a com-
prehensive recent review lists many others (Lam et al., 2015).
In this study, we evaluated the potential of a novel vaccination
approach for dengue infection, based on self-adjuvanting molec-
ular forms designed to deliver multiple copies of the dengue
glycoprotein E domain III to antigen presenting cells
expressing immunoglobulin Fc receptors. Termed PIGS (Poly-
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ImmunoGlobulin Scaffold), these molecules were modelled on
the earlier work of Smith and Morrison (1994) but with the key
modification that the antibody binding domains were replaced
with antigen, resulting in polymeric antigen display. Indeed, this
has been attempted before (Mekhaiel et al., 2011) with the
incorporation of a Plasmodium falciparum antigen but without
the desired outcome, as the polymers appeared less immuno-
genic than the monomers or dimers. In contrast, our study
showed that cEDIII-PIGS alone were highly immunogenic in mice,
and even more so when alum was co-administered. One reason
could be that the functionality of these structures is dependent on
the incorporated antigen but more likely, the difference could be
ascribed to the modifications that were introduced, including the
b-strand of the CH1 domain and hinge region of IgG for flexibility
and the substitution of proline 476 to threonine to make the last
three or four residues of the murine IgG2a or human IgG1 CH3
domain identical to that of murine or human IgM CH4 domain.
Two versions of cEDIII-PIGS molecules were generated using
murine and human immunoglobulin sequences. As a key advan-
tage of cEDIII-PIGS used for antigen display is expected to be in
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relation to effector functions mediated through Ig heavy chain
sequence, we demonstrated their binding to both the C1q
component of complement and Fc receptor bearing cells. Binding
to C1q is the first step in the antibody-mediated activation of the
complement, which leads to a cascade of reactions and formation
of several complement components. While the C3b and C3d
components opsonise pathogens and enhance their phagocyto-
sis, the small components such as C3a, C4a and C5a act as
inflammatory stimuli, contributing to the amplification of the
immune response. The C1q binding ELISA demonstrated that
cEDIII-PIGS bound in a concentration-dependent manner, unlike
the IgG antibody alone, which only showed a moderate level of
binding at the highest concentration tested. The ability of cEDIII-
PIGS to bind complement confirms the presence of polymeric
structures and is also likely to contribute to immunogenicity
in vivo. In another in vitro effector function assay, we tested
whether cEDIII-PIGS could bind to FccRII in a Biacore assay or on
macrophage cells by flow cytometry. As shown in Figure 4, the
cEDIII-PIGS polymers bound more effectively to immobilized FccRII
than monomers and also bound to J774 macrophage but not
NIH-3T3 cells. The macrophage cells express a range of Ig Fc
receptors including FccRI, FccIIa and b, FccRIIIa and b and binding
by polymeric cEDIII-PIGS points to increased uptake and antigen
presentation. Taken together, these in vitro functional assays
clearly demonstrate the potential of cEDIII-PIGS to be delivered
efficiently to the immune system in a self-adjuvanting manner.
This was confirmed by mouse immunization studies which
revealed the mouse cEDIII-PIGS to be highly immunogenic. They
induced an antigen-specific IgG end-point antibody titre of
1:100 000 without adjuvant and 1:1 000 000 with alum, while
immunization with the cEDIII antigen alone induced equivalent
antibody titres only in the presence of alum. No significant
differences were observed between the plants or CHO-cell
expressed cEDIII-PIGS. The antibodies induced were then demon-
strated to have dengue neutralizing activity. We tested neutral-
ization of serotype 2 because it is the most difficult serotype to
vaccinate against, as demonstrated by the suboptimal results for
the Sanofi vaccine (Capeding et al., 2014; Villar et al., 2015), and
also because it is the most predominant serotype in South-East
Asia. While sera from animals immunized with cEDIII antigen
alone failed to neutralize, the sera from one-third of mice
immunized with plant-derived cEDIII-PIGS showed neutralizing
activity. However, the majority of animals showed neutralizing
activity following immunization with cEDIII-PIGS in the presence
of alum, suggesting that the neutralizing potential was depen-
dent on higher antibody titres in those experimental groups. Even
so, the observed DENV2 neutralizing activity was only moderate
and we believe that this is due to the lack of neutralizing epitopes
within cEDIII rather than the overall immunogenic potential of
cEDIII-PIGS. Further improvement could be achieved by modifying
the antigen. To that end, we have already initiated studies in
which the cEDIII had been extended to include the EDI/II hinge
region from the envelope glycoprotein, which has previously been
reported to contribute to its immunogenicity (Messer et al.,
2014).
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Interestingly, the analysis of the IgG subtypes suggested that
cEDIII-PIGS induced significantly more IgG1 (Th2) than IgG2a
(Th1) (Figure 5b), but the analysis of splenocyte cultures indicated
significant induction of the Th1 cytokine IFN-c (Figure 7b). IFN-c
could play an important role in protection against dengue
infection as suggested previously (Gil et al., 2012; Weiskopf
et al., 2013). Indeed, the role of cellular immunity in protection
against dengue infection has been recently re-appraised (Roth-
man et al., 2015) as it seems increasingly plausible that more
than just neutralizing antibodies are required to control viremia.
A growing body of evidence suggests that polyfunctional T
cells play a pivotal role in protective immune responses to
bacterial and viral pathogens (Seder et al., 2008). Whether these
cells are ‘elite’ responders or simply a correlate of an advanta-
geous immune state remains unclear. Regardless, it is apparent
that the gross magnitude of an immune response does not always
correlate with protection, but that the quality of the response
may be a stronger indicator (Darrah et al., 2007). Crucially, it has
been demonstrated that polyfunctional T cells exhibit direct
protective qualities in the context of Dengue virus infection
(Yauch et al., 2009). As we observed significant IFN-c production
in splenocyte cultures from immunized mice, we investigated
further whether this and other Th1 cytokines may be derived
from polyfunctional T cells. Taken together, our data show that
plant- and CHO-derived cEDIII-PIGS induced antigen-specific
cytokine responses from both CD4+ and CD8+ T cells, but with
major qualitative differences compared to cEDIII alone. In CD4+ T
cells, cEDIII immunization resulted in mostly monofunctional cells,
but the mouse groups immunized with cEDIII-PIGS displayed a
high level of T-cell polyfunctionality, containing populations of
memory cells positive for three cytokines that were entirely
absent from the former group. Moreover, in CD8+ T cells, cEDIII-
PIGS were able to induce triple-positive cells. These data strongly
suggest that cEDIII-PIGS induce a superior immunological profile
compared to native antigen, consisting of higher quality effector
T cells.
Interestingly, the addition of alum to cEDIII-PIGS appeared to
decrease total cytokine responses for most groups. Further
analysis of individual cytokines revealed that there was a
consistent reduction in proportion of IFN-c+ cells in response to
alum, particularly in the CD4+ compartment, which is consistent
with its role as an inducer of Th2 polarisation (Brewer et al.,
1999). Pertinently, this observation may also explain why alum
augmented the cEDIII-PIGS-mediated induction of IgG1, as Th2
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cytokines (i.e. IL-4) are known to promote B-cell IgG1 class
switching and IFN-c antagonises this process.
Moving forwards, the results from murine studies justify
progression to human IgG1-based cEDIII-PIGS and it is promising
that these molecules have already been shown to assemble more
efficiently than the murine version and that they are more stable.
An approach that may enhance the Fc effector function of plant-
expressed human cEDIII-PIGS is to engineer the glycans associated
with the Ig heavy chain as was recently demonstrated that FcR
binding of a plant antibody can be enhanced by removal of sugar
residues that are commonly found in plant but not mammalian
glycoproteins (Cox et al., 2006; Forthal et al., 2010).
We observed some differences in immunogenicity between the
two forms of cEDIII-PIGS from CHO cells and N. benthamiana,
notably in splenocyte IFN-c production and T-cell polyfunction-
ality profiles. These could have been due to distinct glycosylation
profiles in plants and animal cells. However, we believe that the
plant expression system offers considerable potential for produc-
ing vaccines on a large scale at a lower cost. This would be
particularly important for developing a dengue vaccine for which
the primary market is the developing world. This proof-of-
principle study provides a clear indication of the potential of the
‘PIGS’ technology as a generic vaccine delivery platform against
dengue and possibly other infectious diseases.
Methods
Gene construction for cEDIII-PIGS
Two construct sets were made, one using murine immunoglob-
ulin sequence—for preliminary evaluation and the other using
human immunoglobulin sequence—for subsequent product
development. Genes encoding the mouse IgG2a-Fc (Fragment
crystallizable) and human IgG1-Fc scaffolds were codon-opti-
mized to Nicotiana tabacum and H. sapiens and synthesized by
Life Technologies, UK. Provided in the pMA-T vector, the
sequences include attB1 and attB2 sites for recombinational
cloning into Gateway vectors. A Kozak consensus sequence
(ACCATGG) allows efficient translation in both plant and
mammalian expression systems. The [ATGC]BsaI-BsaI[GCTT] cas-
sette permits cloning of genes of interest between the leader
sequence and poly-immunoglobulin G Fc scaffold (PIGS)
sequences. This results in the fusion of the gene product of
interest to the N terminus of the Fc polypeptide. To confer
additional flexibility, the scaffold sequence includes the last 9-10
amino acid residues (corresponding to the final b-strand) of the
CH1 domain and hinge region of IgG. Addition of either murine or
human mu-tail piece (ltp) sequence at the 30 terminus results in
polymers with enhanced effector functions (Smith et al., 1995). A
Pro476 ? Thr substitution (Kabat numbering) was included at the
end of the murine IgG2a and human IgG1 CH3 domain. The
rationale for this substitution was to make the last three or four
residues of the murine IgG2a or human IgG1 CH3 domain
identical to the last three or four residues of mouse or human IgM
CH4 domains. The human sequence includes a Cys
230 ? Ser
substitution in the hinge region of IgG1 to remove the Cys residue
that would naturally make a disulfide bond with the terminal Cys
residue of the light chain. In the absence of a light chain, this
substitution is intended to avoid unpaired Cys residues in PIGS
fusion proteins.
DNA encoding the 103 amino acid long consensus dengue
envelope domain III, cEDIII, was amplified using Phusion
High-Fidelity DNA polymerase (NEB) with forward, BsmBI-EDIII-F
(50- ttttCGTCTCAATGCAAGGGCATGTCCTACGCTATG-30) and
reverse primers, BsmBI-EDIII-R (50- ttttCGTCTCAAAGCTGAAGA
ACCCTTCTTGAACCAGTT-30), and the plasmid DNA, pMYV657
(Kim et al., 2013) as the template. The cEDIII PCR fragment-
bearing BsmBI site which is compatible with BsaI sites for cloning
was then cloned into pMA-T plasmid containing either tobacco or
human codon-optimized murine and human version of PIGS
molecules using BsaI restriction enzyme site. For expression in
plants, the construct was then digested by NcoI and XbaI
restriction enzymes and subcloned into the pTRAk.2 vector which
is derivative of pTRAk (Sack et al., 2007).
Expression of cEDIII-PIGS in tobacco cells
For expression of cEDIII-PIGS constructs in plants, both wild type
and a DXF variant of N. benthamiana were used in this study. The
DXF variant produces glycoproteins that resemble mammalian
glycoproteins more closely than the wild-type plant (Strasser
et al., 2008) and for that reason data for functional analysis of
cEDIII-PIGS presented in this study are shown for proteins derived
from DXF plants. The agro-infiltration of plant leaves was
performed with tobacco codon optimized cEDIII-PIGS constructs
alone or in combination with the J chain construct (to generate
hexameric or pentameric molecules, respectively). A 10-mL
starting culture of the transformed agrobacteria was grown for
2 days and used to inoculate a 200-mL culture in YENB medium.
After 1 day, the culture was centrifuged at 4500 g for 15 min
and agrobacteria were re-suspended in the infiltration buffer
(10 mM MES, 10 mM MgCl2) to achieve an OD600 of 0.2. The
agroinfiltration was performed as described previously (Kim et al.,
2015).
Expression of cEDIII-PIGS in mammalian cells
One day before transfection, Chinese Hamster Ovary (CHO) K1
cells (ATCC) were seeded in 24-well tissue culture plates in
culture medium [Dulbecco’s modified Eagle’s medium supple-
mented with 4 mM L-glutamine, 100 U/mL penicillin and
0.1 mg/mL streptomycin (Sigma), and 10% FBS]. For the
generation of codon-optimized cEDIII-PIGS producing cell lines,
the cells were transfected with the expression vectors, encoding
both murine and human versions of cEDIII-PIGS/pEF-DEST51
using the FuGENE6 transfection protocol (Promega). Three days
post-transfection, adherent cells were harvested and plated in
selective medium (containing 7.5 lg/mL of blasticidin) for
1 week, until all non-transfected cells were eliminated. The
remaining cells were plated in 96-well plates in serial dilutions to
allow for selection of single clones and maintained in medium
with 2.5 lg/mL of blasticidin. Supernatants from these clonal
cultures were screened for expression of recombinant protein by
sandwich enzyme-linked immunosorbent assay and by
immunoblotting.
Immunization of mice
For immunization with cEDIII-PIGS, 12- to 16-week-old inbred
male and female Balb/c mice were used. The mice were kept
under defined environmental conditions (12:12-h light:dark
cycle, 19–21 °C, 55% relative humidity, pathogen-free). Five
mice per group were immunized subcutaneously with 15 lg of
plant or mammalian-derived cEDIII-PIGS (equivalent to 4.5 lg of
cEDIII) in 100 lL, with or without aluminium hydroxide gel
(Sigma). Two or three (in two independent experiments)
additional boost immunisations were performed at 2-week
intervals. Mice were bled after each immunization step by tail
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vain, to monitor the antibody titres. Two weeks after the final
immunization, the mice were sacrificed and bled by cardiac
puncture and the spleens were collected for analysis of cellular
immune responses.
Humoral response
Specific humoral responses in sera of mice immunized with
bacterially expressed cEDIII alone or plant and CHO-derived cEDIII-
PIGS were tested by ELISA. 10 lg/mL of recombinant cEDIII
protein was coated on Nunc Maxisorp 96-well ELISA plates and
incubated overnight at 4 °C. After blocking, immunized sera
were added in fivefold serial dilutions and incubated for 2 h at
37 °C. The wells were washed with PBS-T and peroxidase-
conjugated detection antisera [anti-mouse IgG, anti-mouse IgG1
(The Binding Site), or anti-mouse IgG2a-peroxidase (Bio-Rad)]
were added at 1:1000, and incubated as before. Finally, the ELISA
plates were developed by addition of the OPD peroxidase
substrate (Sigma). In a further modification of the ELISA protocol,
immune sera were preincubated with bacterially expressed cEDIII
(10 lg/mL) and were then used to test reactivity in cEDIII- or
cEDIII-coated plates.
Dengue virus neutralization assay
Neutralizing titres of the immune sera were determined as 50%
plaque reduction of viral infectivity against Dengue 2 (New
Guinea C strain, VR-1584 ATCC). Twofold serum dilutions in
Hanks balanced salt solution were prepared and incubated with
50 PFU of the virus for 1 h at 37 °C. The remaining infectivity was
determined by inoculation of BHK-21 cells in the presence of
overlay medium (MEM, 3% carboxymethylcellulose). Plaques
were developed at 5 or 7 days post-infection with a solution of
naphthol blue-black after cell fixation with 10% formaldehyde.
Neutralizing titres were estimated by comparison with irrelevant
sera, as the highest dilution which causes 50% reduction of
plaques.
Intracellular cytokine staining and flow cytometry
To measure T-cell cytokine production and polyfunctionality, 1.5
million splenocytes were pulsed with 5 lg/mL cEDIII in duplicates
in the presence of brefeldin A (5 lg/mL; Sigma-Aldrich, UK) for
4 h. Cells were then incubated with a viability dye (VD) (eFluor
780; 1:1000 dilution, eBioscience, UK) for 30 min at 4 °C,
washed and fixed in 100 lL BD Cytofix (Becton Dickinson, UK) for
30 min at 4 °C and then washed and permeabilized with flow
cytometry buffer (PBS, 0.5% BSA, 0.1% sodium azide; all from
Sigma-Aldrich) containing 0.5% saponin (Sigma-Aldrich) for
intracellular cytokine staining (ICS) using eight-colour polychro-
matic flow cytometry. As negative and positive controls, brefeldin
A-treated cells from each group of mice were either left
unstimulated or treated with an activation cocktail of phorbol
myristate acetate (PMA)/ionomycin (200 ng/mL and 1 lg/mL;
Sigma-Aldrich, UK), respectively.
For ICS, cells were stained for 45 min at 4 °C in flow
cytometry buffer (+0.5% saponin) containing pretitrated anti-
bodies (Biolegend, UK) specific for CD3e (FITC, 145-2C11), CD4
(PerCP-Cy5.5, GK1.5), CD8a (Alexa Flour 700, 53-6.7), IFN-c
(PE-DazzleTM 594, XMG1.2), IL-2 (PE, JES6-5H4), IL-17A (PE-Cy7,
TC11-18H10.1) and TNF-a (APC, MP6-XT22). Cells were then
washed extensively and acquired on a BD LSR II instrument
within 6 h of staining. For panel compensation, UltraComp
eBeads (eBioscience, UK) were used according to the manu-
facturer’s instructions.
Polyfunctional T-cell analysis
All ICS data analysis was performed using FlowJo v.10, MS Excel
2010 and GraphPad Prism v.6 software, using a previously
described protocol (Roederer et al., 2011). Cells were assessed
using the following gating strategy: lymphocyte gate (FSC/
SSC) > singlets (area/height) > viable cells (VDneg) > TCRpos
(CD3+) > T helper (CD4+) or cytotoxic T cells (CD8+). Gating
boundaries were determined by FMOs and biological controls. A
Boolean gating platform was used to assess T-cell polyfunction-
ality. For all analyses, background cytokine production in the
negative control samples was subtracted from the cEDIII-pulsed
cells for each cytokine combination. A cytokine signal threshold
of 0.01% was applied to background-subtracted data and all
subthreshold values were set to zero.
Statistical analysis
The cell culture-based assays were performed in triplicates, and
the values (from a representative experiment of typically three
performed, with the exception of ICS experiment, which was
performed only once) are shown as the mean  standard
deviation. For immunisation experiments, four or five animals
were used per group (in two independent experiments). For all
assays which had more than two experimental variables, Dun-
nett’s multiple comparison test was used, with the exception of
DENV 2 neutralization assay, for which Kruskal–Wallis nonpara-
metric test was used. GraphPad Prism v.6 software was used for
statistical analysis, and the differences were significant when the
P value was 0.05 or less.
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